Clin2
NCT07264998Possibly a fitRecruiting

Gut bacteria study in breast cancer patients on Abemaciclib

Breast NeoplasmsHormone Receptor-Positive Breast CancerAbemaciclibAbemaciclib-related DiarrheaDrug-induced DiarrheaGastrointestinal Microbiome (Focus)Microbiome

Part of Cancer, Skin clinical trials.

This study looks at how gut bacteria changes in people taking Abemaciclib (a breast cancer drug) and whether that relates to diarrhea. It may help find ways to prevent or manage this side effect.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
60 people
Ages
18 years to 75 years
Study type
Observational

Who can take part

  • You are between 18 and 75 years old.
  • You have hormone receptor-positive (HR+) breast cancer.
  • You are currently taking Abemaciclib (with or without hormone therapy) for at least 2 weeks.
  • You do not have major gut diseases (like Crohn’s or colitis) or have had major gut surgery.
  • You have not taken antibiotics, probiotics, or certain herbs in the past month.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07490509Not yet recruiting· Phase 4
Study of abemaciclib and diarrhea risk in breast cancer patients

This trial is for people with hormone receptor-positive breast cancer who are at high risk of recurrence. It looks at how the body processes abemaciclib, a targeted therapy, and whether that affects severe diarrhea, a common side effect.

NCT06621459Recruiting
Study of abemaciclib safety for breast cancer patients

This study looks at real-world safety and side effect management of abemaciclib combined with hormone therapy for patients with RH+, HER2- breast cancer. It aims to understand how well patients tolerate treatment outside of clinical trials.

Brest
NCT07406594Not yet recruiting
Gut microbiome changes during abemaciclib in breast cancer

This study looks at how abemaciclib (Verzenio) affects the bacteria in your gut (the microbiome). If you have a certain type of breast cancer and are starting this treatment, researchers want to understand why it works the way it does.

Burlington, Vermont
NCT07553234Not yet recruiting
Gut Health and Side Effects from Breast Cancer Hormone Treatment

This study looks at how the bacteria in your digestive system may affect side effects from abemaciclib, a hormone-based breast cancer drug. By collecting stool samples, researchers hope to understand which patients might experience fewer problems and how to better manage treatment.

Chicago, Illinois
NCT07605728Recruiting· Phase 2
Probiotics to ease stomach problems from breast cancer treatment

This trial tests whether a special probiotic supplement (good bacteria) can reduce belly discomfort caused by abemaciclib, a hormone therapy drug for early breast cancer. You would take the supplement alongside your cancer treatment to see if it helps with stomach side effects.

Taipei
NCT07599137Not yet recruiting· Phase 4
Testing increasing doses of abemaciclib for early breast cancer

This study tests whether gradually increasing doses of a drug called abemaciclib, combined with hormone therapy, can safely treat early-stage breast cancer that is hormone-positive and HER2-negative. The goal is to find the best dose that works without causing too many side effects.

Hear when a new Breast Neoplasms trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.